Artificial Intelligence In Genomics Market Size, Share - Growth Analysis Report and Forecast Trends 2026-2030

The AI in Genomics market encompasses AI-powered software, platforms, and tools that analyze genomic data to identify patterns, mutations, and biomarkers associated with diseases, drug responses, and genetic conditions. This includes applications in clinical diagnostics, pharmaceutical research, agricultural genomics, and ancestry testing. The market sits at the intersection of biotechnology, artificial intelligence, and healthcare informatics, leveraging advances in deep learning and cloud computing to process the massive datasets generated by next-generation sequencing technologies.

• •Market valuations for 2025 range from roughly $1 billion to over $16 billion depending on research firm methodology and market scope definitions
• •Forecast CAGRs reported by various firms range from approximately 18% to 51%, with most clustering between 35% and 43% over periods extending to 2030-2035
• •Most research firms note that no official government statistical agency publishes dedicated census figures for this market segment

The primary engine of market expansion is the exponential increase in genomic data generation, driven by plunging costs of DNA sequencing and widespread adoption of next-generation sequencing in clinical and research settings. AI technologies enable researchers and clinicians to extract actionable insights from this data far more rapidly and accurately than traditional analytical methods. Additional momentum comes from the pharmaceutical industry's push to accelerate drug discovery using AI, the growing emphasis on precision medicine initiatives worldwide, and increasing clinical adoption of genomic tests for cancer diagnostics and rare disease identification.

• •High-throughput sequencing has reduced the cost of genome sequencing from millions of dollars to under $1,000, creating vast datasets that require AI-driven analysis tools
• •Drug discovery and pharmaceutical R&D represent major demand drivers, as AI can identify drug targets, predict clinical trial outcomes, and personalize treatment regimens
• •Clinical adoption of genomic testing for oncology, hereditary diseases, and pharmacogenomics continues to expand healthcare system investment in AI-enabled genomic platforms

The market is typically segmented by technology type, including machine learning, deep learning, and computer vision, with machine learning representing a dominant segment across most reports. Application-wise, key segments include drug discovery, precision medicine, clinical diagnostics, and agriculture. On the product side, the market covers software platforms, services, and integrated sequencing-AI systems. Regionally, North America leads market share due to strong healthcare infrastructure, major biotech and technology company presence, and favorable regulatory environments, while Asia-Pacific is projected to grow at the fastest rate.

• •Machine learning constitutes the largest technology segment, followed by deep learning, as these methods excel at pattern recognition in complex genomic datasets
• •Drug discovery and precision medicine applications collectively represent the largest end-use segments, driven by pharmaceutical and clinical research investment
• •North America holds the dominant regional position, with Europe and Asia-Pacific following, while emerging markets in Latin America and the Middle East are beginning to adopt AI-genomics solutions

What are the recent trends and outlook?

The integration of multimodal AI, combining genomic data with electronic health records, imaging, and clinical notes, is emerging as a significant trend to improve diagnostic accuracy and treatment recommendations. The development of foundation models for genomics, similar to large language models in NLP, is gaining research attention. Regulatory frameworks for AI-based clinical decision support tools are evolving, particularly in the United States and European Union, which will shape market adoption timelines. Over the coming decade, the convergence of AI and genomics is expected to fundamentally transform drug development pipelines and clinical molecular diagnostics.

• •Multimodal AI systems that integrate genomic data with clinical, imaging, and electronic health record data are emerging to improve comprehensive patient profiling
• •Foundation models trained on large genomic datasets are beginning to show promise for tasks ranging from variant interpretation to gene expression prediction
• •Regulatory pathways for AI-based diagnostic and therapeutic tools are maturing, with agencies developing frameworks for validation and clinical deployment